文献速递前列腺癌

中高危前列腺癌根治术中扩大与局限盆腔淋巴结清扫的早期肿瘤学结局:随机3期试验

Extended Versus Limited Pelvic Lymph Node Dissection During Radical Prostatectomy for Intermediate- and High-risk Prostate Cancer: Early Oncological Outcomes from a Randomized Phase 3 Trial.
PubMed 文献 · Eur Urol · 2020-12-05

这项前瞻性单中心3期试验将300例中高危临床局限前列腺癌患者1:1随机分配至局限盆腔淋巴结清扫(LPLND)或扩大盆腔淋巴结清扫(EPLND),主要终点为生化复发无生存(BRFS)。EPLND未显著改善早期肿瘤学结局,但探索性亚组分析提示活检ISUP分级组3-5患者可能获益。

要点

  • EPLND与LPLND的BRFS无显著差异(HR 0.91,95%CI 0.63-1.32,p=0.6)。
  • EPLND提供更好的病理分期,但早期肿瘤学结局差异未证实。
  • 活检ISUP分级组3-5患者可能从EPLND的BRFS获益,需进一步验证。

核心结论

  • EPLND提供更好的病理分期,但未证明早期肿瘤学结局优于LPLND。
  • 亚组分析提示活检ISUP分级组3-5患者可能从EPLND的BRFS获益,但属假设生成性。

研究设计与样本

  • 前瞻性、单中心、3期随机对照试验,2012年5月至2016年12月随机300例中高危临床局限前列腺癌患者(LPLND 150例,EPLND 150例)。

主要发现

  • LPLND组中位BRFS为61.4个月,EPLND组未达到(HR 0.91,95%CI 0.63-1.32;p=0.6)。
  • 两组中位MFS均未达到(HR 0.57,95%CI 0.17-1.8;p=0.3)。
  • 无患者死于前列腺癌,CSS数据不可用。
  • 探索性亚组分析中,活检ISUP分级组3-5接受EPLND者BRFS更优(HR 0.33,95%CI 0.14-0.74,交互作用p=0.007)。

关键数值与推荐

  • 主要终点为BRFS,试验设计期望EPLND在5年BRFS上显示至少15%的优效。
  • EPLND范围包括闭孔、髂外、髂内、髂总及骶前淋巴结;LPLND仅包括闭孔淋巴结。

临床怎么用

  • EPLND可用于中高危前列腺癌的病理分期,但早期肿瘤学获益未证实。
  • 对活检ISUP分级组3-5患者,EPLND可能改善BRFS,但需更大样本和更长随访验证。

局限性

  • 随访时间短。
  • 存在外科医生异质性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The role of extended pelvic lymph node dissection (EPLND) in the surgical management of prostate cancer (PCa) patients remains controversial, mainly because of a lack of randomized controlled trials (RCTs). OBJECTIVE: To determine whether EPLND has better oncological outcomes than limited PLND (LPLND. DESIGN, SETTING AND PARTICIPANTS: This was a prospective, single-center phase 3 trial in patients with intermediate- or high-risk clinically localized PCa. INTERVENTION: Randomization (1:1) to LPLND (obturator nodes) or EPLND (obturator, external iliac, internal iliac, common iliac, and presacral nodes) bilaterally. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary endpoint was biochemical recurrence-free survival (BRFS). Secondary outcomes were metastasis-free survival (MFS), cancer-specific survival (CSS), and histopathological findings. The trial was designed to show a minimal 15% advantage in 5-yr BRFS by EPLND. RESULTS AND LIMITATIONS: In total, 300 patients were randomized from May 2012 to December 2016 (150 LPLND and 150 EPLND). The median BRFS was 61.4 mo in the LPLND group and not reached in the EPLND group (hazard ratio [HR] 0.91, 95% confidence interval [CI] 0.63-1.32; p = 0.6). Median MFS was not reached in either group (HR 0.57, 95% CI 0.17-1.8; p = 0.3). CSS data were not available because no patient died from PCa before the cutoff date. In exploratory subgroup analysis, patients with preoperative biopsy International Society of Urological Pathology (ISUP) grade groups 3-5 who were allocated to EPLND had better BRFS (HR 0.33, 95% CI 0.14-0.74, interaction p = 0.007). The short follow-up and surgeon heterogeneity are limitations to this study. CONCLUSION: This RCT confirms that EPLND provides better pathological staging, while differences in early oncological outcomes were not demonstrated. Our subgroup analysis suggests a potential BCRFS benefit in patients diagnosed with ISUP grade groups 3-5; however, these findings should be considered hypothesis-generating and further RCTs with larger cohorts and longer follow up are necessary to better define the role of EPLND during RP. PATIENT SUMMARY: In this study, we investigated early outcomes in prostate cancer patients undergoing prostatectomy according to the anatomic extent of lymph node resection. We found that extended removal of lymph nodes did not reduce biochemical recurrence of prostate cancer in the expected range.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Lestingi JFP, Guglielmetti GB, Trinh QD, et al. Extended Versus Limited Pelvic Lymph Node Dissection During Radical Prostatectomy for Intermediate- and High-risk Prostate Cancer: Early Oncological Outcomes from a Randomized Phase 3 Trial. Eur Urol. 2020. PMID: 33293077. doi:10.1016/j.eururo.2020.11.040

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。